PE20121050A1 - Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog - Google Patents
Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehogInfo
- Publication number
- PE20121050A1 PE20121050A1 PE2011002119A PE2011002119A PE20121050A1 PE 20121050 A1 PE20121050 A1 PE 20121050A1 PE 2011002119 A PE2011002119 A PE 2011002119A PE 2011002119 A PE2011002119 A PE 2011002119A PE 20121050 A1 PE20121050 A1 PE 20121050A1
- Authority
- PE
- Peru
- Prior art keywords
- ftalazin
- hedgehog
- piperidin
- trajectory
- pyrazole
- Prior art date
Links
- 241000027355 Ferocactus setispinus Species 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- -1 CYANE Chemical class 0.000 abstract 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21862809P | 2009-06-19 | 2009-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121050A1 true PE20121050A1 (es) | 2012-08-09 |
Family
ID=42332981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011002119A PE20121050A1 (es) | 2009-06-19 | 2010-06-15 | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US8273742B2 (OSRAM) |
| EP (1) | EP2443104B1 (OSRAM) |
| JP (1) | JP5596139B2 (OSRAM) |
| KR (1) | KR101389165B1 (OSRAM) |
| CN (1) | CN102459233B (OSRAM) |
| AR (1) | AR077014A1 (OSRAM) |
| AU (1) | AU2010260244B2 (OSRAM) |
| BR (1) | BRPI1011601A2 (OSRAM) |
| CA (1) | CA2764542C (OSRAM) |
| CL (1) | CL2011003147A1 (OSRAM) |
| CO (1) | CO6480932A2 (OSRAM) |
| CR (1) | CR20110658A (OSRAM) |
| DK (1) | DK2443104T3 (OSRAM) |
| DO (1) | DOP2011000386A (OSRAM) |
| EA (1) | EA019059B1 (OSRAM) |
| EC (1) | ECSP11011541A (OSRAM) |
| ES (1) | ES2409054T3 (OSRAM) |
| HN (1) | HN2011003139A (OSRAM) |
| HR (1) | HRP20130408T1 (OSRAM) |
| IL (1) | IL216599A (OSRAM) |
| JO (1) | JO2931B1 (OSRAM) |
| MA (1) | MA33363B1 (OSRAM) |
| MX (1) | MX2011014029A (OSRAM) |
| MY (1) | MY156667A (OSRAM) |
| NZ (1) | NZ596882A (OSRAM) |
| PE (1) | PE20121050A1 (OSRAM) |
| PL (1) | PL2443104T3 (OSRAM) |
| PT (1) | PT2443104E (OSRAM) |
| SG (1) | SG177289A1 (OSRAM) |
| SI (1) | SI2443104T1 (OSRAM) |
| TN (1) | TN2011000627A1 (OSRAM) |
| TW (1) | TWI385165B (OSRAM) |
| UA (1) | UA106755C2 (OSRAM) |
| WO (1) | WO2010147917A1 (OSRAM) |
| ZA (1) | ZA201108587B (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201071248A1 (ru) * | 2008-04-29 | 2011-06-30 | Эли Лилли Энд Компани | Дизамещенные фталазиновые антагонисты пути hedgehog |
| HRP20130527T1 (en) * | 2008-11-03 | 2013-07-31 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| CA2743264C (en) * | 2008-11-17 | 2014-02-18 | Julia Marie Clay | Tetrasubstituted pyridazines hedgehog pathway antagonists |
| CA2743483C (en) | 2008-11-17 | 2014-03-11 | Eli Lilly And Company | Tetrasubstituted pyridazine hedgehog pathway antagonists |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
| EP2688565A1 (en) | 2011-03-23 | 2014-01-29 | Semorex Technologies Ltd. | Treatment of proliferative disorders with a chemiluminescent agent |
| GB201309508D0 (en) * | 2013-05-28 | 2013-07-10 | Redx Pharma Ltd | Compounds |
| GB201311953D0 (en) * | 2013-07-03 | 2013-08-14 | Redx Pharma Ltd | Compounds |
| WO2015073691A1 (en) | 2013-11-14 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating cancer by activation of bmp signaling |
| CN105017140B (zh) * | 2014-04-28 | 2017-12-29 | 复旦大学 | 邻氨基苯甲酰胺化合物及其制备方法和用途 |
| GB2528298A (en) * | 2014-07-16 | 2016-01-20 | Redx Pharma Plc | Compounds |
| CN105985321B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 吡唑酞嗪化合物及其制备方法和用途 |
| CN105985319B (zh) * | 2015-02-11 | 2019-02-26 | 复旦大学 | 芳基酞嗪化合物及其制备方法和用途 |
| CN105985320B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 苄基酞嗪化合物及其制备方法和用途 |
| BR112017026103B1 (pt) | 2015-06-04 | 2023-10-03 | Sol-Gel Technologies Ltd | Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos |
| EP3303289A4 (en) * | 2015-06-05 | 2018-11-14 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
| EA201892075A1 (ru) | 2016-03-15 | 2019-04-30 | Оризон Дженомикс, С.А. | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей |
| CN106279114B (zh) * | 2016-08-04 | 2019-01-29 | 东南大学 | 一种Taladegib的合成方法 |
| US10548908B2 (en) | 2016-09-15 | 2020-02-04 | Nostopharma, LLC | Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification |
| CN106831718B (zh) * | 2016-12-30 | 2019-05-07 | 上海科技大学 | 平滑受体配体及其应用 |
| WO2018211007A1 (en) | 2017-05-18 | 2018-11-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of mast cell diseases |
| WO2021261601A1 (ja) | 2020-06-26 | 2021-12-30 | ラクオリア創薬株式会社 | レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬 |
| JP2023546536A (ja) * | 2020-10-13 | 2023-11-02 | エンデバー バイオメディシンズ， インコーポレイテッド | 線維症を処置する方法 |
| WO2025188802A1 (en) | 2024-03-05 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of improving lung function |
| WO2025189041A1 (en) * | 2024-03-07 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| WO2025242197A1 (zh) * | 2024-05-24 | 2025-11-27 | 成都思倍博医药科技有限公司 | 氘代的Hedgehog通路SMO受体抑制剂 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN148482B (OSRAM) * | 1977-06-03 | 1981-03-07 | Pfizer | |
| JP4169368B2 (ja) | 1996-01-15 | 2008-10-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 脈管形成阻害性ピリダジンアミン |
| EP1067939B1 (en) | 1998-04-09 | 2015-09-16 | The Johns Hopkins University | Use of steroidal alkaloid derivatives as inhibitors of hedgehog protein signaling pathways |
| DE60016402T2 (de) | 1999-06-08 | 2005-10-27 | Lorantis Ltd. | Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges |
| JP4658473B2 (ja) * | 2001-07-27 | 2011-03-23 | キュリス，インコーポレイテッド | ヘッジホッグシグナル伝達経路メディエーター、それに関連した組成物及び利用 |
| EP1496905B1 (en) * | 2002-04-22 | 2008-08-13 | Johns Hopkins University School of Medicine | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| AU2003265853A1 (en) | 2002-08-29 | 2004-03-19 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
| US8067608B2 (en) | 2003-09-29 | 2011-11-29 | The Johns Hopkins University | Hedgehog pathway antagonists |
| WO2005080378A1 (ja) | 2004-02-24 | 2005-09-01 | Mitsubishi Pharma Corporation | 縮合ピリダジン誘導体 |
| CN1984904A (zh) | 2004-05-08 | 2007-06-20 | 神经能质公司 | 3－芳基－5,6－二取代哒嗪 |
| EP1789390B1 (en) | 2004-09-02 | 2011-11-09 | Genentech, Inc. | Pyridyl inhibitors of hedgehog signalling |
| EP1900731A1 (de) * | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
| AU2008225766B2 (en) | 2007-03-15 | 2012-06-07 | Novartis Ag | Organic compounds and their uses |
| AU2008269128B2 (en) * | 2007-06-25 | 2012-08-02 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| AU2008300019A1 (en) | 2007-09-07 | 2009-03-19 | Amgen Inc. | Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling |
| EA017918B1 (ru) * | 2007-12-13 | 2013-04-30 | СИЕНА БИОТЕК С.п.А. | Антагонисты пути hedgehog и их терапевтические применения |
| EA201071248A1 (ru) * | 2008-04-29 | 2011-06-30 | Эли Лилли Энд Компани | Дизамещенные фталазиновые антагонисты пути hedgehog |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| AU2009279760B2 (en) * | 2008-08-04 | 2012-07-12 | Amgen Inc. | Aurora kinase modulators and methods of use |
| HRP20130527T1 (en) | 2008-11-03 | 2013-07-31 | Eli Lilly And Company | Disubstituted phthalazine hedgehog pathway antagonists |
| CA2743264C (en) | 2008-11-17 | 2014-02-18 | Julia Marie Clay | Tetrasubstituted pyridazines hedgehog pathway antagonists |
| CA2743483C (en) | 2008-11-17 | 2014-03-11 | Eli Lilly And Company | Tetrasubstituted pyridazine hedgehog pathway antagonists |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
-
2010
- 2010-06-08 AR ARP100102003A patent/AR077014A1/es active IP Right Grant
- 2010-06-10 JO JO2010188A patent/JO2931B1/en active
- 2010-06-11 TW TW099119158A patent/TWI385165B/zh not_active IP Right Cessation
- 2010-06-15 PL PL10726756T patent/PL2443104T3/pl unknown
- 2010-06-15 CA CA2764542A patent/CA2764542C/en not_active Expired - Fee Related
- 2010-06-15 MA MA34455A patent/MA33363B1/fr unknown
- 2010-06-15 MX MX2011014029A patent/MX2011014029A/es active IP Right Grant
- 2010-06-15 HR HRP20130408AT patent/HRP20130408T1/hr unknown
- 2010-06-15 AU AU2010260244A patent/AU2010260244B2/en not_active Ceased
- 2010-06-15 EP EP10726756.9A patent/EP2443104B1/en active Active
- 2010-06-15 WO PCT/US2010/038568 patent/WO2010147917A1/en not_active Ceased
- 2010-06-15 JP JP2012516178A patent/JP5596139B2/ja active Active
- 2010-06-15 KR KR1020117030157A patent/KR101389165B1/ko not_active Expired - Fee Related
- 2010-06-15 PE PE2011002119A patent/PE20121050A1/es active IP Right Grant
- 2010-06-15 DK DK10726756.9T patent/DK2443104T3/da active
- 2010-06-15 NZ NZ596882A patent/NZ596882A/xx not_active IP Right Cessation
- 2010-06-15 ES ES10726756T patent/ES2409054T3/es active Active
- 2010-06-15 PT PT107267569T patent/PT2443104E/pt unknown
- 2010-06-15 SG SG2011094190A patent/SG177289A1/en unknown
- 2010-06-15 EA EA201270049A patent/EA019059B1/ru not_active IP Right Cessation
- 2010-06-15 CN CN201080027189.3A patent/CN102459233B/zh active Active
- 2010-06-15 BR BRPI1011601A patent/BRPI1011601A2/pt not_active Application Discontinuation
- 2010-06-15 SI SI201030200T patent/SI2443104T1/sl unknown
- 2010-06-15 MY MYPI2011006137A patent/MY156667A/en unknown
- 2010-06-15 UA UAA201114996A patent/UA106755C2/uk unknown
- 2010-06-15 US US12/815,439 patent/US8273742B2/en active Active
-
2011
- 2011-11-22 ZA ZA2011/08587A patent/ZA201108587B/en unknown
- 2011-11-24 IL IL216599A patent/IL216599A/en not_active IP Right Cessation
- 2011-11-29 HN HN2011003139A patent/HN2011003139A/es unknown
- 2011-12-07 TN TNP2011000627A patent/TN2011000627A1/en unknown
- 2011-12-08 CR CR20110658A patent/CR20110658A/es unknown
- 2011-12-13 DO DO2011000386A patent/DOP2011000386A/es unknown
- 2011-12-14 CL CL2011003147A patent/CL2011003147A1/es unknown
- 2011-12-16 EC EC2011011541A patent/ECSP11011541A/es unknown
- 2011-12-22 CO CO11177210A patent/CO6480932A2/es not_active Application Discontinuation
-
2012
- 2012-08-21 US US13/590,481 patent/US9000023B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20211700A1 (es) | Compuesto heterociclico y su uso | |
| PE20142301A1 (es) | Uracilos sustituidos biciclicamente y uso de los mismos | |
| PE20110433A1 (es) | Antagonistas de la via hedgehog de ftalazina disustituida | |
| PE20140934A1 (es) | Derivados de pirazol | |
| PE20141203A1 (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
| PE20120650A1 (es) | Acetamidas sustituidas por n-(hetero)-arilo y 2-(hetero)-arilo, como moduladores de la senalizacion de wnt | |
| ATE483707T1 (de) | 2-cyclopropylthiazolderivate | |
| UY28885A1 (es) | 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s) | |
| PE20081755A1 (es) | Nuevas 2-aminooxazolinas como ligandos taar1 | |
| PT1716152E (pt) | Compostos heterocíclicos fundidos e sua utilização como antagonistas do receptor metabotrópico para o tratamento de distúrbios gastrointestinais | |
| PE20090890A1 (es) | Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c | |
| PE20090839A1 (es) | Derivados de isoxazol-imidazol | |
| BRPI0810402A2 (pt) | Derivados de pirrolidina como antagonistas duais dos receptores nk1/nk3 | |
| PE20080056A1 (es) | Derivados de cromencarboxamida como antagonistas del receptor s1p1 | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| PE20091653A1 (es) | Derivados sustituidos de pirazol y su uso | |
| CL2011001848A1 (es) | Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. | |
| DK2081572T3 (da) | Benzimidazol-cannabinoid-agonister med en substitueret heterocyklisk gruppe | |
| PE20181015A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| PE20140968A1 (es) | Derivados de benzamida sustituida | |
| PE20160846A1 (es) | Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c | |
| UY29184A1 (es) | Derivados de sulfonilbencimidazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |